This overlapping grouping in this study was an intentional exploratory analysis designed to explore different clinical cutoffs for HER-2 expression intensity, in order to maximize the pathological significance of HER-2 expression for prostate cancer prognosis. This evidence concerns the gene ERBB2 and Familial prostate cancer.